Table 1 Patient characteristics recorded before the start of benralizumab therapy (i.e., at the index date or during the 12 months prior to the index date)
Characteristics | Evaluable population N = 205 |
|---|---|
Age at the index date, yrs | 55.8 ± 13.3 |
Female sex | 126 (61.5%) |
BMI at the index date, kg/m2 (N = 182) | |
Under/Normal weight | 70 (38.5%) |
Overweight | 79 (43.4%) |
Obese | 33 (18.1%) |
Smoking status at the index date (N = 195) | |
Non-smoker | 139 (71.3%) |
Previous smoker | 50 (25.6%) |
Current smoker | 6 (3.1%) |
Age at asthma diagnosis, yrs (N = 203) | 38.9 ± 16.7 |
Asthma duration at the index date, yrs (N = 203) | 12.4 (6.3–24.6) |
SEA duration at the index date, yrs (N = 203) | 1.6 (1.0–3.1) |
Atopy at the index date | 85 (41.5%) |
Comorbidities at the index date | |
≥ 1 current asthma-related condition | 103 (50.2%) |
Chronic rhinosinusitis | 50 (24.4%) |
GERD | 43 (21%) |
Allergic conjunctivitis | 28 (13.7%) |
Allergic rhinitis | 45 (22%) |
Other (atopic dermatitis, urticaria, etc.) | 17 (8.3%) |
≥ 1 current OCS-related condition | 77 (37.6%) |
Hypertension | 46 (22.4%) |
Osteoporosis | 23 (11.2%) |
Cataract | 12 (5.9%) |
Anxiety/Depression | 11 (5.3%) |
Type 2 Diabetes Mellitus | 10 (4.9%) |
Obstructive sleep apnoea | 10 (4.9%) |
Cardiovascular disease | 7 (3.4%) |
Other OCS-related ongoing comorbidities | 19 (9.3%) |
≥ 1 other ongoing comorbidities | 35 (17.1%) |
Thyroid disorders | 8 (3.9%) |
Bronchiectasis | 6 (2.9%) |
Blood eosinophil count at the index date, cells/mm3 | 580 (400–850) |
Total serum IgE at the index date, IU/mL (N = 123) | 289 (85–573) |
Exacerbations during the 12 months prior to the index date (N = 196) | |
≥ 1, any severity | 182 (92.9%) |
AER | 4.03 |
≥ 1 mild | 101 (51.5%) |
≥ 1 moderate | 121 (61.7%) |
≥ 1 severe | 79 (40.3%) |
AER | 1.10 |